Altered Metabolism of Low-Density Lipoprotein and Very-Low-Density Lipoprotein Remnant in Autosomal Recessive Hypercholesterolemia
Authors:
- Hayato TadaHayato Tada
- Masa-Aki KawashiriMKMasa-Aki Kawashiri
- Katsunori IkewakiKIKatsunori Ikewaki
- Yoshio TeraoYTYoshio Terao
- Tohru NoguchiTNTohru Noguchi
- Chiaki NakanishiCNChiaki Nakanishi
- Masayuki TsuchidaMTMasayuki Tsuchida
- Mutsuko TakataMTMutsuko Takata
- Kenji MiwaKMKenji Miwa
- Tetsuo KonnoTKTetsuo Konno
- Kenshi HayashiKHKenshi Hayashi
- Atsushi NoharaANAtsushi Nohara
- 1 February 2012
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Genetics
- Vol. 5 (1) , 35-41
Abstract
Background—: Autosomal recessive hypercholesterolemia (ARH) exhibits different responsiveness to statins compared with that in homozygous familial hypercholesterolemia (FH). However, few data exist regarding lipoprotein metabolism of ARH. Therefore, we aimed to clarify lipoprotein metabolism, especially the remnant lipoprotein fractions of ARH before and after statin therapy. Methods and Results—: We performed a lipoprotein kinetic study in an ARH patient and 7 normal control subjects, using stable isotope methodology (10 mg/kg of [ 2 H 3 ]-leucine). These studies were performed at baseline and after the 20 mg daily dose of atorvastatin. Tracer/tracee ratio of apolipoprotein B (apoB) was determined by gas chromatography/mass spectrometry and fractional catabolic rates (FCR) were determined by multicompartmental modeling, including remnant lipoprotein fractions. FCR of low-density lipoprotein (LDL) apoB of ARH was significantly lower than those of control subjects (0.109 versus 0.450±0.122 1/day). In contrast, the direct removal of very-low-density lipoprotein remnant was significantly greater in ARH than those in control subjects (47.5 versus 2±2%). Interestingly, FCR of LDL apoB in ARH dramatically increased to 0.464 1/day, accompanying reduction of LDL cholesterol levels from 8.63 to 4.22 mmol/L after treatment with atorvastatin of 20 mg/d for 3 months. Conclusions—: These results demonstrate that ARH exhibits decreased LDL clearance associated with decreased FCR of LDL apoB and increased clearance for very-low-density lipoprotein remnant. We suggest that increased clearance of remnant lipoprotein fractions could contribute to the great responsiveness to statins, providing new insights into the lipoprotein metabolism of ARH and the novel pharmacological target for LDLRAP1.Keywords
This publication has 26 references indexed in Scilit:
- The E32K variant of PCSK9 exacerbates the phenotype of familial hypercholesterolaemia by increasing PCSK9 function and concentration in the circulationAtherosclerosis, 2010
- A novel method for determining functional LDL receptor activity in familial hypercholesterolemia: Application of the CD3/CD28 assay in lymphocytesClinica Chimica Acta, 2009
- Human LDL Receptor Enhances Sequestration of ApoE4 and VLDL Remnants on the Surface of Hepatocytes but Not Their Internalization in MiceArteriosclerosis, Thrombosis, and Vascular Biology, 2008
- Identification of a VLDL‐induced, FDNPVY‐independent internalization mechanism for the LDLRThe EMBO Journal, 2007
- Atherogenic remnant lipoproteins: role for proteoglycans in trapping, transferring, and internalizingJournal of Clinical Investigation, 2007
- Disruption of LDL but not VLDL clearance in autosomal recessive hypercholesterolemiaJournal of Clinical Investigation, 2007
- Atorvastatin improves diabetic dyslipidemia and increases lipoprotein lipase activity in vivoAtherosclerosis, 2004
- Autosomal Recessive HypercholesterolemiaSeminars in Vascular Medicine, 2004
- Autosomal recessive hypercholesterolemia in a Sicilian kindred harboring the 432insA mutation of the ARH geneAtherosclerosis, 2003
- Lovastatin therapy in receptor-negative homozygous familial hypercholesterolemia: Lack of effect on low-density lipoprotein concentrations or turnoverThe Journal of Pediatrics, 1988